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Abstract
Background: Expression of higher eukaryotic genes as soluble, stable recombinant proteins is still
a bottleneck step in biochemical and structural studies of novel proteins today. Correct
identification of stable domains/fragments within the open reading frame (ORF), combined with
proper cloning strategies, can greatly enhance the success rate when higher eukaryotic proteins are
expressed as these domains/fragments. Furthermore, a HTP cloning pipeline incorporated with
bioinformatics domain/fragment selection methods will be beneficial to studies of structure and
function genomics/proteomics.
Results: With bioinformatics tools, we developed a domain/domain boundary prediction (DDBP)
method, which was trained by available experimental data. Combined with an improved cloning
strategy, DDBP had been applied to 57 proteins from C. elegans. Expression and purification results
showed there was a 10-fold increase in terms of obtaining purified proteins. Based on the DDBP
method, the improved GATEWAY cloning strategy and a robotic platform, we constructed a high
throughput (HTP) cloning pipeline, including PCR primer design, PCR, BP reaction, transformation,
plating, colony picking and entry clones extraction, which have been successfully applied to 90 C.
elegans genes, 88 Brucella genes, and 188 human genes. More than 97% of the targeted genes were
obtained as entry clones. This pipeline has a modular design and can adopt different operations for
a variety of cloning/expression strategies.
Conclusion: The DDBP method and improved cloning strategy were satisfactory. The cloning
pipeline, combined with our recombinant protein HTP expression pipeline and the crystal
screening robots, constitutes a complete platform for structure genomics/proteomics. This
platform will increase the success rate of purification and crystallization dramatically and promote
the further advancement of structure genomics/proteomics.
Background
One of the results from genome sequencing projects, such
as the human genome project, is to promote the develop-
ment of structural genomics/proteomics endeavors which
focus on the large-scale determination of protein struc-
tures and functions. The traditional cloning and expres-
sion approach is inadequate for such a daunting task, and
high throughput (HTP) methods are clearly necessary
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[1,2]. An integrated robotic pipeline can streamline the
complex experimental procedures and makes it possible
to carry out gene cloning and protein expression for a
large amount of targets in a timely and reproducible man-
ner. Some groups have developed the HTP cloning
method including the design of nested primers for PCR
cloning [3], while we have also developed an automated
pipeline for recombinant protein expression, applying the
GATEWAY cloning/expression technology and a stepwise
automation strategy on an integrated robotic platform [4].
The robotic pipeline is fully operational and has produced
a large number of soluble recombinant proteins in E. coli
using the open reading frame cDNA library (ORFeome)
for C. elegans and human genomes [5,6].
However, the success rate of expressing soluble proteins is
limited when the full length ORF was used to express the
target protein. In a number of cases, including our own
results, soluble proteins could be expressed in E. coli when
a smaller fragment derived from the ORF was used for
expression [7-10]. We have identified smaller protein frag-
ments from spontaneous degradation and limited prote-
olysis, and recloned them for expression [7,8]. Compared
to expressing soluble proteins carrying GATEWAY tags
due to cloning artifacts, the soluble expression rate was
increased from 1.3% to 27.6% when the GATEWAY tags
were not included, and a 41.7% rate of soluble expression
was achieved when the identified fragment without both
GATEWAY tag encoded sequences was recloned (data not
shown). The GATEWAY tags named here refer to the
amino acid sequences TSLYKKAGX and TQLSCTKW,
resulted from the recombination site attB1 or attB2,
respectively, generated by the GAETWAY LR reaction [11].
X refers to the amino acid that depends on the coding
sequence. With pET15g as the expression vector, which
was engineered using pET15b (Novagen) to be compati-
ble with GATEWAY cloning [4], the final N-terminal tag
sequences in the originally and newly cloned genes are
MGSSHHHHHHSSGLVPRGSQSTSLYKKAGX  and
MGSSHHHHHHSSGLVPRGSQSTSLYKKAGLVPRGS
respectively, in which HHHHHH is the his-tag followed
by a thrombin cleavage site (LVPR|GS, named thrombin
site I, the cutting site is between R and G) deprived from
pET15b vector, TSLYKKAG is the N-terminal GATEWAY
tag generated by GATEWAY LR reaction, and the last
LVPRGS is the newly introduced thrombin site (named
thrombin site II) that is used to eliminate the N-terminal
GATEWAY tag. No C-terminal GATEWAY tag was present
in the newly cloned genes by the introduction of a stop
codon after the coding sequence. Thus the clones in which
GATEWAY tags were included expressed a recombinant
protein that had Sequence I, i.e. GSQSTSLYKKAGX at the
N-terminus and Sequence II, i.e. TQLSCTKW at the C-ter-
minus in addition to the coding sequence after the his-tag
was removed by protease digestion through the thrombin
site I. In the clones without the GATEWAY tags, the recom-
binant protein contained only GS at the N-terminus in
addition to the coding sequence. More recently, 23 frag-
ments were recloned and 6 of them have resulted in dif-
fracting quality crystals, which led to 3 structures [7,8].
These findings suggested that the sequences derived from
GATEWAY tags affect the soluble expression and a well
folded fragment/domain of the target protein is best
suited for expression of a soluble recombinant protein in
E. coli. In fact, 90% of the structures of human proteins
deposited in the Protein Data Bank (PDB) [12] comprise
a fragment of the gene. We therefore modified our robotic
pipeline to incorporate an automatic operation that can
select a proper domain/fragment from the ORF for recom-
binant protein expression and used new cloning strategy
described above.
New bioinformatics tools and cloning methods were
developed and adopted to the previously established
robotic pipeline, as discussed in this report. The major
modifications included the automatic design of PCR
primers, and improved multi-step laddered PCR, fol-
lowed by previously established micro BP reaction of
GATEWAY cloning, transformation, plating of trans-
formed E. coli cells (DH5α), colony picking and entry
clone plasmid DNA extraction. The automated cloning
module is combined with our automated protein expres-
sion module that consists of construction of expression
clones in 96-well plates, protein solubility profiling by
dynamic ELISA, as a protein expression platform for struc-
tural genomics/proteomics. The cloning module is flexi-
ble and efficient to carry out different cloning strategies as
shown here.
A number of algorithms for predicting domain bounda-
ries have been developed previously [13-18]. Most of
them, however, are not publicly available or cannot be
adapted to our HTP pipeline. We report here a new com-
posite scheme to locate domains with relatively accurate
boundaries. Programs included in the scheme are Inter-
Pro/InterProScan [19,20] and Domain Linker Finder [16],
BLAST [21], SignalP [22,23] and TMHMM [24]. The
BLAST alignment and signal peptide, transmembrane
(TM) region prediction were combined with the results of
InterPro/InterProScan and Domain Linker Finder to
define the fragment for cloning. This composite method
has been validated with experimental results.
Results and discussion
HTP cloning of 366 ORFs
The GATEWAY system is a suitable method for HTP clon-
ing in 96-well plates. However, when entry clones (gener-
ated with pDONR201) and the expression vector pET15g
are combined by the LR reaction, the recombination
sequence attB1 may add additional unwanted 9 aminoBMC Biotechnology 2007, 7:45 http://www.biomedcentral.com/1472-6750/7/45
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acids (TSLYKKAGX) at the N-terminus if the insert is
downstream from a fusion peptide, and the attB2 site may
add TQLSCTKW at the C-terminus if no stop codon fol-
lows the coding sequence. We named sequences from
attB1 and attB2 as the GATEWAY tags. The additional
amino acids derived from GATEWAY tags may interfere
with subsequent experiments, such as soluble expression
of the recombinant protein, purification problems due to
aggregation of the protein, and crystallization of the pro-
tein (see descriptions in Background). It is therefore desir-
able to engineer a protease (thrombin here) cleavage site
(PCS) after attB1 (Figure 1). A stop codon was also added
right after the coding sequence in primer design to elimi-
nate the extra amino acids at the C-terminus due to GATE-
WAY cloning. After the protein is purified, all amino acids
prior to PCS, i.e. MGSSHHHHHHSSGLVPRGSQST-
SLYKKAGLVPR, can be removed by the protease cleavage.
Compared with the clones in which GATEWAY tags were
included, newly cloned and expressed recombinant pro-
teins contained only GS at the N-terminus in addition to
the coding sequence. And if no new PCS was introduced,
expressed proteins would have Sequence I, i.e. GSQST-
SLYKKAGX at the N-terminus and Sequence II, i.e. TQLS-
CTKW at the C-terminus in addition to the coding
sequence after the his-tag was removed by protease diges-
tion through the thrombin site I (For details, see Back-
ground). Since the PCS was included in the primer
synthesis in our strategy and the long forward primer
would be costly and could increase the chance of errors,
we designed a PCR strategy using two forward primers and
two reverse primers (see Methods: Primer design and the
PCR protocol for HTP cloning). This strategy has two
advantages: only short primers are required, and primer
F2, R2 could be synthesized in bulk. Such measures signif-
icantly reduce the cost and the error rate in 96-well oper-
ations.
A comprehensive computer program has been developed
to carry out primer designs for selected genes. Usually the
length of the gene-specific nucleotides in the entire primer
should be maintained between 20 to 30 bases according
to the manufacturer's manual [25] and our previous expe-
rience. The length of gene-specific oligos in this program
is therefore set in this range. Since PCR clones are to be
carried out in 96-well plates, conditions for all wells, such
as denaturation time, cycle number, are the same even
though each well represents a different gene. Therefore in
addition to grouping coding regions with a similar length
in one plate, we also chose to design primers that would
result in a similar melting temperature (Tm). The best
value for Tm was about 60°C for our experiments, so we
tried to make the Tm of all oligos as close to 60°C as pos-
sible by adding or subtracting one base at a time. Besides
the length of oligos, the salt concentration can also affect
the Tm. In our program, the salt concentration was set at
10 mM. After the gene-specific oligo was designed with
optimal Tm, sequences corresponding to attB1 or attB2,
PCS and a stop codon were added. The primer design pro-
gram was written in PERL, which could be easily modified
to accommodate changes in primer sequences.
After receiving primers for 90 C. elegans, 88 Brucella, and
188 human ORFs in 96-well plate, HTP cloning (Figure
A multi-step laddered PCR Protocol Figure 2
A multi-step laddered PCR Protocol. With this proto-
col, template DNA was amplified for 34 cycles with 5 min-
utes at 95°C for initial denaturation, 20 second at 94°C for 
denaturation, 30 second for annealing, 140 second at 68°C 
for extension and 10 minutes at 68°C for final extension. 
Annealing temperature was variable: it started from a rela-
tively high temperature (55°C), and then decreased 1–2 
degree each time until to 46°C. The temperature again 
increased 5 degree and stabilized at 51°C.
The primer design strategy using two pairs of primers Figure 1
The primer design strategy using two pairs of prim-
ers. Primer F2 and R2 contained attB sites and no gene spe-
cific region, which could be synthesized in bulk; Primer F1 
and R1 contained gene specific sequences and an overlap 
region with Primer F2 and R2. CDS stands for coding 
sequence and a protease cleavage site was engineered after 
attB1 site.BMC Biotechnology 2007, 7:45 http://www.biomedcentral.com/1472-6750/7/45
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3), including PCR, E-Gel check, BP reaction, transforma-
tion, colony picking, cell culture and mini-prep, was per-
formed on our integrated robotic platform. From 366
attempted amplifications, 337 PCR products could be
detected by E-Gel (Figure 4). Interestingly, 20 vectors, out
of 29, whose PCR products could not be detected by E-Gel
could still be transformed and obtained as entry clones
successfully. This phenomenon has also been observed by
other research groups [26]. Including clones that were
derived from PCR products not detectable by E-Gel, but
transformed successfully, our PCR protocol showed a suc-
cess rate of 97.5%. Our follow-up results suggested that
PCR determines the final success rate of the whole HTP
cloning process (Table 1), whereas other steps, such as BP
reaction, transformation, have negligible effects on the
final outcome. Finally 96.7% ORFs were obtained as entry
clones, which were verified by PCR/E-Gel check.
Validation of domain identification
Proteins are usually composed of multiple domains con-
nected by linkers. Removal of flexible tails or separation
of fragments would yield more compact and stable pro-
tein fragments that are more suitable for expression of a
soluble recombinant protein and subsequent studies
including crystallization, as demonstrated by data pre-
sented below. We aimed at developing an integrated strat-
egy, named DDBP (domain/domain boundary
prediction), to predict domain boundaries and stable
fragments within the full length protein coded by the
ORF. In this strategy, InterPro/InterProScan, PDB hom-
ology alignment, and Domain Linker Finder were the core
methods used for domain prediction. In addition, signal
peptide prediction by SignalP and TM regions prediction
by TMHMM provided supplementary information for
more accurate prediction.
InterPro is an integrated database that consists of most of
the essential databases for domain and function site avail-
able today, such as PFAM [27], ProDom [28], SMART
[29], PRINTS [30], PROSITE [31], TIGRFAM [32], SUPER-
An E-Gel test result for entry clones of the second plate of  94 human genes Figure 4
An E-Gel test result for entry clones of the second 
plate of 94 human genes. 2% E-Gel® 96 Agarose with E-
Gel® Low Range Quantitative DNA Ladder were used in the 
test.
A schematic representation of HTP cloning and expression  pipeline with the aid of bioinformatics tools Figure 3
A schematic representation of HTP cloning and 
expression pipeline with the aid of bioinformatics 
tools. In above HTP cloning pipeline, some steps, which 
were marked with star, were not performed on BiomekFX 
robot. ExtractCDS and BatchPrimer were two PERL pro-
grams used for extraction of the DNA coding sequence from 
a full-length sequence (ORF) and design of gene specific prim-
ers.
Table 1: Statistic of PCR and entry clone success rates of HTP 
cloning
all PCR (success rate) entry clone (success rate)
C. elegans 90 85 (94.4%) 83 (92.2%)
Human 188 184 (97.9%) 183 (97.3%)
Brucella 88 88 (100%) 88 (100%)
Total 366 357 (97.5%) 354 (96.7%)BMC Biotechnology 2007, 7:45 http://www.biomedcentral.com/1472-6750/7/45
Page 5 of 14
(page number not for citation purposes)
FAMILY [33], etc. InterProScan, which is used together
with InterPro database, is a tool that combines different
protein signature recognition methods into one resource.
Since InterPro contains many different domain and func-
tion site databases, conflicted results often appear when
different databases were used. Moreover, InterPro/Inter-
ProScan analysis could only predict the core region of a
domain, but not the domain boundaries. To improve the
prediction accuracy, Domain Linker Finder (DLF), which
applies the neural network method to distinguish domain
linker sequences from non-linker sequences, was used to
confirm domain prediction results obtained by InterPro/
InterProScan, and to define more accurately the domain
boundaries.
As the first step of DDBP, prediction of the signal peptide
and the TM region for each ORF was carried out by Sig-
nalP and TMHMM, respectively. The identified signal pep-
tide was eliminated as an unstable region, and TM regions
would be treated as domain linkers that were later inte-
grated into the results from DLF. The second step is to per-
form BLAST analysis against the PDB database to find
potential domain relevant information. Finally InterPro/
InterProScan and DLF programs were executed.
When results of InterPro/InterProScan and DLF were
available, further analyses were performed: (1) if results of
InterPro/InterProScan can be confirmed by PDB align-
ment results, manually integrate them and decide com-
mon domain boundary positions. For example, protein 3-
H6, i.e. NP_508026 (Figure 5A), which comprises 431
amino acids, has no signal peptide and TM regions
according to the prediction of SignalP and TMHMM. The
result of InterPro/InterProScan showed this protein con-
tains three possible domains/fragments: Domain1 (24–
118), Domain2 (141–234) and Domain3 (254–370).
While PDB alignment results showed: (a) the region 4–
131 of 3-H6 is homologous to the region 20–147 of a
149-Amino-acid protein (PDB ID: 1ROU, containing 1
domain) with 60% identity; (b) the region 4–244 of 3-H6
is similar to the region 41–280 of a 280-amino-acid pro-
tein (PDB ID: 1Q1C, containing 2 domains) with 48%
identity; (c) the region 7–408 of 3-H6 is similar to the
region 24–422 of a 457-amino-acid protein (PDB ID:
1KTO/A, containing 3 domains) with 40% identity; (d)
the region 128–428 of 3-H6 is similar to the region 22–
330 of a 336-amino-acid protein (PDB ID: 1P5Q/A, con-
taining 2 domains) with 35% identity. The results from
InterPro/InterProScan prediction appear to be consistent
with the results of PDB alignments. By combining these
two results, three protein fragments were selected for 3-
H6: 1–131, 128–244, and 245–431 as the stable region.
(2) if results of InterPro/InterProScan and PDB align-
ments were not consistent, but one of two results could be
confirmed by DLF, the consistent results were manually
combined and domain boundary positions were
assigned. TM regions were integrated with the result from
DLF at this stage as well. For example, 11020-H6, i.e. the
region 299–792 of NP_493412 (Figure 5B), a 494-amino-
acid protein without TM regions and a signal peptide, was
predicted to have three possible domains/fragments by
InterPro/InterProScan (Fragment1: 53–225; Fragment2:
236–494; Fragment3: 337–475) and no homologous pro-
tein structures were found by PDB alignment. DLF results
showed that protein 11020-H6 may contain five possible
domain linkers (DL1: 19–52; DL2: 106–145; DL3: 215–
241; DL4: 325–330; DL5, 373–383), in which DL1 and
DL3 were consistent with Fragment1, the N-terminal end
of Fragment2; and DL4 was consistent with the N-termi-
nal end of Fragment3. DL2 was ignored. Since Fragment3
was contained within Fragment2, it is possible that
Fragment2 might contain at least two domains, and
Fragment3 might be one of them. The final predicted sta-
ble domains/fragments of 11020-H6 were: 53–225, 236–
494 and 331–494; (3) if results of InterPro/InterProScan
and PDB alignments were not consistent, and no result
from DLF was available or the DLF prediction didn't sup-
port any results from InterPro/InterProScan or PDB align-
ments, the N-terminus and C-terminus of the ORF would
be treated as domain boundaries. After completing the
prediction, a final check was performed to ensure that the
region between two predicted domain boundaries should
be at least 80 amino acids. If a predicted domain con-
tained less than 80 amino acids, one of the two domain
boundaries with a less reliability would be omitted and
the domain was joined to the next domain/fragment,
except that positive PDB alignment results were available
and supported that the short predicted domain was long
enough to form a stable domain.
In order to validate this combination scheme, we con-
structed a dataset that contains the definition of 47
domains/fragments from our experimental results (see
Method: Datasets for domain/domain boundaries predic-
tion) and made a comparison between the experimental
and DDBP prediction results (Table 2). In the compari-
son, the experimentally determined domain/domain
boundaries are assumed to be correct domain/domain
boundaries. For a protein, whatever how many domains it
contained or were predicted, if only two boundaries of
one predicted domain were same with those of one cor-
rect domain, or its ranges < = +10 aa, this prediction
would be as an accurate prediction. Similarly, if 10 aa <
ranges < = +30 aa, the prediction would be as a basically
accurate prediction, and if range > +30 aa, the prediction
would be as a wrong prediction. For example, protein
11011-D8 (Table 2) has one experimental determined
domain: 45–190. With DDBP method, it was predicted
with two possible domains: 1–107 or 52–190. Because
one of predicted domains (52–190) was consistent withBMC Biotechnology 2007, 7:45 http://www.biomedcentral.com/1472-6750/7/45
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the correct result, i.e. ranges (52-45 = 7 and 190-190 = 0)
< = +10 aa, this prediction was as a accurate prediction.
Protein 4-F5 (Table 2) has one experimentally determined
domain (1–144) and its predicted domains by DDBP
method were 1–124 and 143–269. By comparison, 4-F5
was thought as a basically accurate prediction because its
ranges (1-1 = 0 and 144-124 = 20) < = +30 and > +10 aa.
The complete comparison for all 47 domains were listed
in Table 2, as showed that more than 60% of the predic-
tion was consistent with experimental results, in which
43% was accurate (labeled with I in the column A) and
19% was basically accurate (labeled with II in the column
A).
Application of the DDBP method and the improved 
cloning strategy
We applied the DDBP method and the improved cloning
strategy to see if the success rate for obtaining purified sol-
uble recombinant proteins would be greatly improved
when the predicted fragments were cloned for expressing
recombinant proteins in E. coli. The test dataset includes
57 proteins from C. elegans ORFeome version 3.1, whose
expression/purification data of ORFs using the same
expression vector were available from previous experi-
ments. For these 57 proteins, the coding regions corre-
sponding to the DDBP predicted fragments were
subjected to HTP cloning, and the expression/purification
pipeline, in which 14 ones were shortened constructs.
Two examples for interpreting DDBP (domain/domain boundary prediction) method Figure 5
Two examples for interpreting DDBP (domain/domain boundary prediction) method. A: According to the predic-
tion of Interpro/InterProScan, 3-H6 (NP_508026), a 431-amino-acid protein that has no TM region or the signal peptide, pos-
sibly contained three domains: Domain1 (24–118), Domain 2 (141–234), and Domain 3 (254–370). a, b, c, d on the right of 
horizontal lines mark four separate alignment results between protein 3-H6 and Protein Data Bank (PDB) database. a: the 
region 4–131 of 3-H6 is homology with the region 20–147 of 1ROU with 60% identity; b: the region 4–244 of 3-H6 was similar 
to the region 41–280 of 1Q1C with 48% identity; c: the region 7–408 of 3-H6 was similar to the region 24-422 of a 1KTO/A 
with 40% identity; d: the region 128–428 of 3-H6 was similar to the region 22–330 of 1P5Q/A with 35% identity. By combining 
the results of Interpro/InterProScan and alignments, three protein fragments (1–131, 128–244, and 245–431) were selected for 
3-H6 as stable domains/fragments. B: 11020-H6 (corresponding to the region 299–792 of protein NP_493412), a 494-amino-
acid protein that has no TM regions or the signal peptide, was predicted to have three possible domains/fragments (Fragment1: 
53–225; Fragment2: 236–494; Fragment3: 337–475) by InterPro/InterProScan (shown on top). DLF results showed that pro-
tein 11020-H6 may contain five possible domain linkers (DL1: 19–52; DL2: 106–145; DL3: 215–241; DL4: 325–330; DL5, 373–
383) (shown at the bottom). The stable domains/fragments of 11020-H6 were predicted as 53–225, 236–494 and 331–494 by 
the DDBP method (shown as the conclusion in the box at right).B
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Table 2: Comparisons between experimental and DDBP prediction results*
A B C D E F G H IJK
I 11058-C7 249 no no 4–190; 1–220; 
80–190
no 24%, (7–240/8–268, 288); 
26%, (4–240/7–225, 251)
(1–249)# 1–249 NP_506406 F20G2.1
I 11048-D3 199 no no 9–199 76–98, 181–181 26%, (5–160/3–164, 208) (1–199)$ 1–199 NP_502315 F35G2.2
I 11011-D8 190 no no 8–36, 47–75, 83–
111; 2–107;
148–172, 108–
120, 82–92, 49–
51
27%, (37–105/1–69, 146) (45–190)& 1–107, 52–190 NP_493641 F23F1.2
I 18-A2 210 no no 29–79; 108–194 no 30%, (75–193/4–115, 135) (74–210)& 75–210 NP_491893 BAG1 (human) 
homolog family 
member (bag-1)
I 11033-F3 208 no no 6–74; 128–194; 
1–97; 80–207
39–56 31%, (2–207/1–197, 198) (1–208)# 1–208 NP_496863 Glutathione S-
Transferase family 
member (gst-16)
I 11-D11 346 no no 80–317; 55–320; 
219–317
19–34, 116–126 31%, (76–334/36–291, 298) (56–346)& 55–346 NP_491872 C55B7.3
I 11104-F4 370 no no 2–221, 1–370 126–143, 348–
352, 19–25, 71–
82, 292–297, 
233–237
34%, (128–347/15–231, 
265)
(125–370, 1–
124)&
1–125, 128–347 NP_001040820 Cell Division 
Cycle related 
family member 
(cdc-37)
I 79-D4 401 no no 65–395; 37–400 66–108, 27–45, 
108–125, 217–
236, 138–146
35%, (212–395/2– 185, 185) (206–401)# 212–401 NP_491735 C06A5.7b
I 9-H3 212 no no no 19–52, 162–192, 
79–89
35%, (86–136/84– 131, 217) (59–212)$ 53–212 NP_493365 Y40B1B.5
I 76-D4 254 no no 2–171; 3–250; 
139–167
139–147 36%, (3–251/8–265, 278) (1–254)# 1–254 NP_001021765 Y47G6A.22
I 8-C1 142 no no 4–140 no 46%, (5–141/9–149, 150) (1–142)& 1–142 NP_499813 T12D8.6
I 11-F6 327 no 209– 231,
246– 268
207–227, 246–
266
56–95, 19–56, 
95–136, 136–161
50%, (141–167/1– 28, 163) (1–182, 1–145)& 1–135 NP_491774 T09B4.5a
I 1-F11 229 no no 148–217; 170–
201; 170–212
19–21, 129–134 59%, (135–220/20–107, 
113)
(135–229)# 135–229 NP_506367 F53F4.3
I 3-H6 431 no no 24–118, 141–234; 
254–370; 261–
370
397–413, 214–
225, 100–107, 
123–128
60%, (4–131/20–147, 149); 
48%, (4–244/41–280, 280); 
40%, (7–408/24–422, 457); 
35%, (128–428/22–330, 
336);
(1–135)# 1–131, 128–244, 
245–431
NP_508026 FK506-Binding 
protein family 
member (fkb-6)
I 20-H6 496 no no 38–496; 186–261, 
293–363, 422–
483; 183–272, 
275–374, 422–
487
120–151, 265–
279
66%, (394–496/1– 103, 104) 
; 75%, (183–269/1– 87, 90); 
75%, (290–366/1– 78, 85)
(169–385, 386–
496)&
183–272, 290–
366, 394–496
NP_001022967 U2AF splicing 
factor family 
member (uaf-1)
I 1-D10 206 1–21 no 41–198; 23–77, 
85–141, 143–196
no no (23–206)# 22–206 NP_491320 R12E2.13
I 11020-H6** 494 no no 53–225; 337–475; 
336–453; 236–
494
19–52, 106–145, 
215–241, 373–
383, 325–330
no (1–237, 238–494) 
&$
53–225, 236–494, 
331–494
NP_493412 Y37H9A.3
I 70-H8 130 no 107– 129 109–129 19–104 no (1–130)# 1–130 NP_491052 W03D8.3B
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I 8-C9 183 no no 125–159; no no (1–183)# ; (28–
183, 23–183)$
1–183 NP_510277 BMP receptor 
Associated 
protein family 
member (bra-1)
I 11005-B8 245 no no no 19–20, 129–136, 
41–46
no (9–245)# 1–245 NP_740981 R05F9.1b
II 18-F7 288 no no 34–286 19–30, 72–78, 
196–202, 66–70
45%, (35–286/21– 274, 276) (32–266)$ 34–286 NP_001021584 EXOnuclease 
family member 
(exo-3)
II 4-F5 592 no no 189–269 485–509, 125–
142, 19–37, 369–
382,99–109, 311–
317
35%, (210–269/15–74, 76); (1–144)& 1–124, 143–269 NP_494544 C16C8.16
II 11011-C6 162 no no 4–162; 5–54, 71–
132
51–68 no (1–148, 1–124)& 1–162 NP_500324 F42A6.6
II 11058-H2 249 no no 4–190; 4–230; 4–
209
no 40%, (5–245/23– 263, 267) (1–222)$ 1–249 NP_506407 F20G2.2
II 76-F10 263 no no 23–130; 33–109 118–126, 20–20 27%, (27–120/6–98, 108) (1–129)& 21–130 T26031 hypothetical 
protein W01A8.2
II 79-H11 245 no no 2–156, 1–241 144–181, 181–
204, 121–144
51%, (2–154/2–154, 155) (1–185)$ 1–156 NP_492567 C03D6.5
II 25–B11 302 no no 23–127; 45–114 203–236, 19–24, 
236–248, 146–
161, 187–195
no (1–153)& 23–145 NP_492781 B0511.7
II 11-D3 313 no no 28–214; 9–302 151–174, 19–22 no (1–313)# ; (213–
313)$
23–313 NP_001021333 Suppressor of 
PResenilin defect 
family member 
(spr-2)
II 11058-F12 272 no no 40–63; 40–68, 
90–124
no 32%, (67–119/3–54, 60); 
26%, (40–119/5–84, 87); 
31%, (41–114/36– 113, 124)
(1–147)& 1–124 NP_503566 F36F12.8
III 20-D7 500 no no 311–395; 41–278; 
283–436
387–417, 288–
308, 453–469, 
481–482
28%, (342–432/68–153, 
289)
(1–500)# ; (298–
500, 388–500, 
407–500)$
1–287, 283–452 NP_491868 lariat 
DeBRanching 
enzyme related 
family member 
(dbr-1)
III 37-G9 245 no no no 206–227, 19–21 no (1–102, 103–
245)&
1–245 NP_507040 F14H3.6
III 70-D2 265 1–25 15–37 69–243 223–247, 195–
199
22%, (128–264/13–121, 
135)
(1–130, 1–174)& 1–265 AAC25860 Hypothetical 
protein C37C3.3
III 2-B6 316 no no 27–294 225–260, 174–
191, 149–163, 
296–298, 71–82, 
84–84, 219–220
23%, (53–168/46– 180, 201) (71–294)# ; (104–
316)$&
1–295 NP_501422 D2096.8
III 10-E5 274 no no 1–80, 108–190 229–246, 193–
213
25%, (17–161/32– 166, 196) (65–237, 1–74, 
75–274)&
1–192 NP_502380 C25G4.6
III 3-D2 419 no no 95–128, 133–166; 
93–197; 133–166
196–217, 41–62, 
259–275, 341–
351, 19–21
26%, (95–239/13– 144, 
166); 32%, (99–197/8–95, 
118)
(140–309, 290–
419)&
93–197, 93–258 NP_495087 C17G10.2
Table 2: Comparisons between experimental and DDBP prediction results* (Continued)B
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III 113-H8 588 no no 232–342; 241–
334
492–515, 19–56, 
81–132, 150–185
29%, (234–328/2– 85, 105) (1–345, 34–313)& 232–342 NP_740981 R05F9.1b
III 76-F6 803 no 769– 791 17–250, 558–652; 
10–34, 111–148, 
382–402
752–767, 19–24, 
717–727, 280–
281
29%, (62–257/5– 200, 205); 
29%, (83–257/1– 175, 181)
(1–181)& 25–257 NP_491008 alpha-CaTuliN 
(catenin/vinculin 
related) family 
member (ctn-1)
III 4-A4 569 no no 164–338, 369–
527;187–200, 
206–222, 263–
279, 305–321, 
321–335, 506–
527; 263–318, 
388–452, 511–
568
65–97, 19–
38,112–139
32%, (154–567/18–397, 
402)
(334–542, 334–
501)&; (1–569)#
154–549 NP_495753 associated with 
RAN (nuclear 
import/export) 
function family 
member (ran-3)
III 25-H8 339 no no 24–84; 24–75 215–276, 111–
169, 187–201, 
100–109
41%, (22–75/7–61, 70) (1–152)& 1–99 NP_495652 T09A5.8
III 2-H9 356 no no 22–273; 1–108, 
115–297; 13–284
192–215, 303–
312, 338
42%, (1–284/1–289, 382) (1–335, 1–356) 
$&
1–197 NP_497949 T23F11.1
III 18-H1 208 no no 32–124; 36–113; 
24–45, 51–68, 
131–145, 164–
181, 186–205
171–190, 114–
171, 19–40
43%, (41–110/10– 76, 90) (1–81)&$ 32–124 NP_510410 HIStone family 
member (his-24)
III 11049-D6 435 no no 293–433; 270–
433
110–152, 234–
260, 175–186, 
375–381
no (1–156)# ; (9–
158, 1–119)$&
261–435 NP_001041025 Y41E3.7a
III 9-G11 250 no no 1–194 228–232 no (35–250)& 1–227 NP_497076 R05H10.1
III 10-E1 251 no no no 158–199 no (1–206)& 1–251 NP_496943 W01G7.4
III 37-F11 230 no no 1–230 106–126, 168–
182
no (45–179, 45–
230)&
1–230 NP_507024 T10C6.5
III 75-A8 228 no no no 19–44, 125–135 no (1–189)$& 1–228 NP_492509 F46A9.1
III 11048-E2 262 no no 33–178; 61–179 183–198 no (1–262)$ 1–182 NP_501337 MEChanosensory 
abnormality family 
member (mec-17)
* column A: Prediction accuracy level (I, accurate; II, basically accurate; III, wrong) and Plate-ID, users could query/search the sequence relative information from the SGCE web site [41]; column B: 
number of amino acids in the ORF; column C: signal peptide prediction results using SignalP; column D: transmembrane region prediction results using TMHMM; column E: domains/fragments from 
Interpro/InterProScan analysis; column F: domain linker regions predicted by Domain Linker Finder; column G: PDB-alignment results, including the percentage of sequence identity, query/subject 
sequence start position and end position, and the length of the subject sequence; column H: experimental results from protein crystal/three-dimensional structures (labeled with #), limited 
proteolysis (labeled with $) or spontaneous degradation (labeled with &); column I: DDBP prediction results; J: Accession Number, user could obtain sequence relative information from National 
Center for Biotechnology Information (NCBI) [40]; K: Definition of the protein or ACEID for proteins without known functions.
** 11020-H6 is corresponding to the region 299–792 of NP_493412.
Table 2: Comparisons between experimental and DDBP prediction results* (Continued)BMC Biotechnology 2007, 7:45 http://www.biomedcentral.com/1472-6750/7/45
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Previously, all full-length proteins in this dataset, with the
GATEWAY tags included at the N-terminus and the C-ter-
minus, were treated as soluble by the 96-well expression
profiling when expressed in E. coli. However, all but two
proteins could not be purified from E. coli lysates prepared
for expressing these proteins. Most of the recombinant
proteins in this dataset were either unstable or formed
large aggregates as shown by gel filtration chromatogra-
phy. In contrast, after employing the DDBP method and
improved cloning strategy that avoids GATEWAY encoded
sequences, 50 proteins were expressed as soluble (Table 3,
Figure 6), and until now, at least 20 were successfully puri-
fied (Table 3, Figure 7), among which four proteins had
been crystallized (data not shown), despite that seven
proteins were insoluble (Table 3, Figure 6). There is a 10-
fold increase in terms of obtaining purified proteins from
this dataset, as shows the combination of DDBP method
and our cloning strategy is successful and results in a
clearly improved protein expression and purification.
However we do not know whether the observed improve-
ment mainly deprives from a correct domain prediction
since most proteins in our testing set only have the short-
ened or the full length construct and the completely com-
parison cannot be done.
NP_506094 and NP_492301 are two only proteins with
shortened and full length constructs in the test dataset.
Notably, the shortened constructs of these two proteins
are successfully expressed and purified, while their full
length constructs are not soluble or cannot be purified.
Though this result has no statistic meaning for DDBP
method, it at least affirms that the DDBP is an effective
method for some kinds of protein to find proper domain/
fragment from the ORF for recombinant protein expres-
sion.
Conclusion
In this paper we presented an effective HTP cloning pipe-
line and a domain/domain boundary prediction (DDBP)
strategy. With this pipeline, four 96-well plates of genes
could be cloned into an expression vector in seven days.
After integrating the domain/domain boundary predic-
tion strategy, the success rate of purification and crystalli-
zation was shown to increase dramatically. Moreover, this
cloning pipeline, combined with our recombinant pro-
tein HTP expression pipeline and the crystal screening
platform, constitutes a complete platform for structure
genomics/proteomics. In the next stage, we will improve
the accuracy of bioinformatics analysis of domain and
domain boundaries and automates all bioinformatics
procedures.
Methods
Genes for HTP cloning
A total of 90 genes from C. elegans ORFeome version 3.1
[5], 188 human genes from Human ORFeome versions
1.1 [6], and 88 genes from Brucella melitensis ORFeome
version 1.1 [26] were used for evaluating the automated
cloning modules. The cDNAs were provided by Dr. Vidal's
group at Harvard Medical School as entry clones.
Datasets for domain/domain boundaries prediction
Domain definition for 47 proteins was derived from
experimental results and the dataset was used for validat-
ing the domain/domain boundary prediction scheme.
Among them, some domains were defined by protein
crystals/three-dimensional structures; some were defined
by limited proteolysis or spontaneous degradation (Table
2). The stable fragment from degraded samples was
sequenced from the N-terminus and its molecular weight
Soluble expression results of 57 proteins used for testing  DDBP method Figure 6
Soluble expression results of 57 proteins used for 
testing DDBP method. ELISA results for soluble expres-
sion at 18°C and 37°C. Different shades in panels stand for 
different expression levels: the dark gray for the higher level, 
the gray for the medium level, the white for the lower level 
and the black for those not expressed, which was decided by 
comparisons with the positive control (A12 and B12, each 
containing one soluble protein). If ELISA readings of OD 
(optical density) at 405 nm was higher than or the same with 
the lower value of positive controls, the protein in this well 
was considered as expressed. Well C12 and D12 are nega-
tive controls and blank wells (white with no numbers) are 
null. After comparing the results at 18°C and 37°C, seven 
proteins (well B10, C10, E3, F3, G8, H3, and H9) were con-
sidered as not soluble.BMC Biotechnology 2007, 7:45 http://www.biomedcentral.com/1472-6750/7/45
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Table 3: Constructs, soluble expression and purification results of 57 proteins used for testing DDBP method
Well
Row Column Accession Number Start 
position
End 
position
Length 
(aa)
Protein definition Soluble 
expression level 
(18°C)
Soluble 
expression 
level (37°C)
Purified
A 2 NP_493355 1 300 300 C01A2.5 medium high yes
A 3 NP_001022737 1 264 264 X-box Binding Protein homolog family 
member (xbp-1)
medium high not
A 7 NP_498947 1 282 282 PeRoXisome assembly factor family 
member (prx-19)
high high Yes
A 9 NP_497226 1 253 253 W06E11.4 medium medium not
A 10 T26925 1 195 195 hypothetical protein Y45F10C.5 medium not soluble not
A 11 NP_495146 1 218 218 K05F1.9 medium high not
B 1 NP_495062 1 210 210 Helix Loop Helix family member (hlh-
26)
high high not
B 2 NP_496422 1 225 225 B0491.3 high low Yes
B 3 NP_495475 1 197 240 F10E7.2 not soluble low not
B 4 NP_496547 21 284 284 W03C9.1 medium high not
B 5 NP_496156 29 184 184 R53.8 low high not
B 8 NP_501161 1 250 250 F42C5.3 medium high Yes
B 9 NP_502163 1 319 319 C10C6.3 high high Yes
B 10 NP_500772 55 348 368 ZK354.6 not soluble not soluble not
B 11 NP_501789 1 297 297 F25H8.1 high high Yes
C 1 NP_501895 1 294 294 R09E10.1 medium high Yes
C 2 NP_500890 1 243 243 H32C10.2 high high not
C 3 NP_501981 1 388 388 R102.5a low low not
C 4 NP_507039 1 196 196 F14H3.5 high low not
C 5 NP_506094 1 183 183 F23H12.3 medium low not
C 6 NP_506094 1 90 183 F23H12.3 not soluble medium Yes
C 8 NP_505964 20 260 260 T04F3.2 medium medium not
C 9 NP_506495 1 252 252 D1086.4 high high not
C 10 NP_741113 1 394 419 C32A3.3a not soluble not soluble not
C 11 NP_501199 1 299 299 F55G1.9 not soluble low not
D 1 NP_495021 1 197 197 EEED8.12 high high not
D 6 NP_502315 1 199 199 F35G2.2 high high Yes
D 10 NP_491869 1 232 232 MeDiaTor family member (mdt-18) medium low not
E 1 NP_501936 1 190 190 F01D4.5b medium low not
E 2 NP_506929 26 144 206 F57A10.4 not soluble low not
E 3 NP_506929 26 206 206 F57A10.4 not soluble not soluble not
E 5 NP_491210 1 249 249 T12F5.1 high high not
E 7 NP_506245 35 240 240 R186.3 low not soluble not
E 8 NP_495941 1 269 308 T24H10.1 high medium Yes
E 10 NP_510298 1 269 269 AMP-Activated Kinase Beta subunit 
family member (aakb-1)
medium low not
F 1 NP_492285 1 239 239 F02E9.5 medium low not
F 2 NP_509787 1 195 195 F13E6.1 medium high not
F 3 AAZ82857 1 230 230 Hypothetical protein C17H12.13 not soluble not soluble not
F 4 NP_493382 1 210 210 Y87G2A.10 high medium Yes
F 5 NP_497990 1 214 214 C38D4.9 high high Yes
F 10 NP_498391 1 217 217 C56G2.15 high high Yes
G 2 NP_493230 1 183 183 W02A11.2 high not soluble Yes
G 3 NP_492005 1 189 189 F22D6.2 high high Yes
G 4 NP_492692 1 206 206 Y106G6E.4 high medium Yes
G 5 NP_492795 1 207 207 C34B2.5 high medium Yes
G 6 NP_491736 1 214 214 C06A5.2 medium high not
G 7 NP_491358 1 233 233 ZK973.9 low medium not
G 8 NP_492301 1 240 240 D1081.9 not soluble not soluble not
G 9 NP_492301 1 65 240 D1081.9 high high Yes
G 11 NP_491721 1 273 273 B0207.11 high high not
H 2 NP_491965 1 274 274 T21G5.4 high low Yes
H 3 NP_491348 1 287 287 Y47D9A.2a not soluble not soluble not
H 4 NP_491903 27 330 363 D2092.4 high medium not
H 5 NP_496803 1 183 183 F15D4.2 medium low not
H 6 NP_491434 1 177 177 C10H11.7 low low not
H 8 NP_495527 30 179 179 F45E12.5b high high Yes
H 9 NP_494315 1 276 276 F22E5.8 not soluble not soluble notBMC Biotechnology 2007, 7:45 http://www.biomedcentral.com/1472-6750/7/45
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was determined by mass spectrometry. The domain defi-
nition was derived from the gene by starting at the N-ter-
minus as sequenced and adding more amino acids in the
gene sequence till the molecular weight matched that
determined by mass spectrometry. This dataset was used
to calibrate the domain/fragment prediction algorithm.
Another dataset that has no relevant experimental infor-
mation for domain definition was also used to examine
this prediction method. This dataset included 57 proteins
from  C. elegans ORFeome version 3.1. Full-length
sequences in this dataset have been inserted into expres-
sion vectors previously for expressing recombinant pro-
teins in E. coli with the GATEWAY tags (data not shown).
Bioinformatics tools
BLAST [21] was used for alignments between our selected
sequences and PDB [12] sequences. InterPro/InterProS-
can [19,20,36], was used to identify domain/fragment(s)
of the ORF selected for generating a stable protein
domain/fragment. Domain Linker Finder (DLF) [16,37]
was used for finding possible domain linker regions. Sig-
nalP [22,23,38] and TMHMM [24,39] were used for pre-
diction of the signal peptide and transmembrane (TM)
regions. ExtractCDS, written in PERL, was developed as
reported here and was used for extracting proper coding
regions corresponding to selected domains. BatchPrimer,
a comprehensive primer design program, was also devel-
oped here to carry out the batch primer design for the
selected sequences.
Primer design and the PCR protocol for HTP cloning
We designed a PCR strategy of using two forward primers
(F1, F2) and two backward primers (R1, R2) (Figure 1),
modified from the strategy described by Kagawa and col-
leagues [34]. Primer F1 contains a part of the protease
cleavage site followed by the gene specific sequence of 5'-
terminus: CCACGCGGCAGC- 5'gene specific sequence.
Primer R1 contains a part of the attB2 site followed by the
gene specific sequence of the 3'-terminal: CAAGAAAGCT-
GGGTTA-3' gene specific sequence. Primer F2 contains
the attB1 and the protease cleavage site:
GGGGACAAGTTTGTACAAAAAAG CAGGCTTGGT-
GCCACGCGGCAGC, and R2 contains attB2 and the ter-
mination codon: GGGGACCACTTTGTACAAGAAAGC
TGGGTTA. Gene specific regions in F1 and R1 are
designed by BatchPrimer that would result in a pair of
primers with a similar melting temperature (Tm) by
adjusting the oligo length. The final Tm calculation was
based on the formula of Breslauer and his colleagues [35],
in which the salt concentration was set to 10 mM. The
length of gene-specific oligos in the program was limited
to between 20 to 30 bases according to our previous
experimental results.
Different DNA polymerases and different protocols were
investigated. After a number of tests, we selected Accu-
Prime™ Pfx (Invitrogen) as our final choice of DNA
polymerase, and a corresponding multi-step laddered
PCR protocol was devised as described in Figure 2. PCR
starts with primers F1, F2 (F1:F2 = 1:10) and R1, R2
(R1:R2 = 1:10) [34] for 34 cycles. Amounts of oligos, tem-
plates and the polymerase are decided according to Accu-
Prime™ Pfx user manual.
Gateway cloning and small-scale protein expression
After running the batch PCR protocol, 96-well E-Gel (Inv-
itrogen) was used to check PCR outcomes. Entry clones
were generated with entry vector pDONR201 (Invitrogen)
and the PCR products by the BP reaction. BP reaction and
transformation of DH5α cells were performed according
to the GATEWAY protocols from the manufacturer (Invit-
rogen). Mini-prep was carried out with QIAGEN 96-well
mini-prep kits. Expression vectors were prepared in 96-
well plates with the selected entry clones and vector
Purification results of 57 proteins used for testing DDBP  method Figure 7
Purification results of 57 proteins used for testing 
DDBP method. Purification results for 15 of the 20 purified 
proteins. The name of each SDS-PAGE gel includes 2 parts, 
for example B2 (NP_496422), B2 corresponds to the well 
showed in Figure 6 and Table 3, and NP_496422 is the acces-
sion number of the protein in the public database [40]. The 
bands labeled with ''Cut'' in the figure correspond to the 
results after the cleavage by the thrombin and those labeled 
with ''Uncut'' correspond to the results before the cleavage. 
''Aa'' in the figure stands for the amino acid range of the puri-
fied proteins.BMC Biotechnology 2007, 7:45 http://www.biomedcentral.com/1472-6750/7/45
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pET15g [4], via the LR reaction. Expression vectors were
plated, and single colonies were selected for mini-prep.
All above procedures (Figure 3), except for colony picking,
were automated in our integrated robotic pipeline, oper-
ating mainly on a BiomekFX robot, as previously
described [4].
For protein expression, expression vectors were trans-
formed into E. coli BL21(DE3)AI firstly. Then pick single
colonies for recombinant protein expression. After over-
night growth at 37°C, the bacteria were diluted (1:200)
into 0.6 ml culture containing 100 μg/ml ampicillin in
two 96-well block assay plates. After growing for 3–4
hours, without monitoring the absorbance of the culture,
protein expression was induced at 18°C and 37°C by
addition of IPTG to a final concentration of 1 mM. Protein
expression was carried out for 3 hours at 37°C and 20
hours at 18°C.
Cell lysis and Enzyme-linked Immunosorbent Assay (ELISA)
After protein expression, cells were spun down at 4000
rpm for 30 minutes and cell pellets were lysed by freezing
overnight at -80°C and then thawed at room temperature
for 15 minutes. Cell lysis was continued by shaking for 30
minutes at 1000 rpm in Vortemp shakers after the addi-
tion of 500 μl native lysis buffer (50 mM NaH2PO4, 300
mM NaCl, 10 mM imidazole, and 1 mg/ml lysozyme, pH
8.0). After lysis, plates were spun at 4000 rpm for 30 min-
utes and a Beckman Biomek FX robot was used to separate
the supernatant, which contained only soluble proteins
and was used for the solubility analysis of recombinant
proteins by a dynamic indirect enzyme-linked immuno-
sorbent assays (ELISA) protocol, from the pellet.
Indirect ELISAs were carried out on a Beckman/Sagian
core system: an ORCA robotic arm (Beckman) for moving
plates, a Biomek 2000 (Beckman) for handling liquid, a
Biotek plate washer (Bio-Tex Instruments) for washing
plates, and a SpectraMax plate reader (Molecular Devices)
for recording and analyzing results. A mouse anti-His tag
antibody (Anti-Penta-His, QIAGEN) was used as the pri-
mary antibody at a dilution of 1:500 and a rabbit anti-
mouse IgG Fc alkaline phosphatase conjugate (Pierce)
was used as the secondary antibody also at a dilution of
1:500. p-Nitrophenyl phosphate (ICN) was used to stain
according to the manufacturer's instructions. After read
absorbance at 405 nm for 6 hours, with an interval of 30
minutes, the results were electronically compiled and
automatically scored with in-house software.
Large scale expression/purification of soluble proteins and 
thrombin cleavage of purified proteins
Based on results of ELISA, we performed large scale
expression on the possible soluble proteins with same
protocols as described above, except enlarging the culture
volume from 0.6 ml to 6 liters and inducing cells when
absorbance values at 595 nm reached 0.6 to 0.8. After the
appropriate incubation (3 hours at 37°C or 20 hours at
18°C), cells were harvested by centrifugation (7000 rpm
for 12 minutes). Cell pellets were then re-suspended in
appropriate amount of binding buffer (for Ni-His6 affin-
ity column, 20 mM Tris, 500 mM NaCl, 5 mM imidazole,
and 0.01% NaAzide, pH 7.9) and completely lysed by
sonicating. After centrifuge lysate for 30 minutes at 17000
rpm, remove the pellet and filter lysate through Watmann
paper.
Collected proteins were firstly purified by use of the Ni-
nitrilotriacetic acid agarose (Qiagen) affinity chromatog-
raphy: the protein mixture was loaded to the column, and
after washed the column, the proteins were eluted under
native conditions (500 mM imidazole, 20 mM Tris, 500
mM NaCl, 0.01% NaAzide, pH7.9). Obtained proteins
were then concentrated, and further purified by use of the
standard protocols with ion-exchange (Hitrap Q column,
Amersham) and size exclusion chromatography
(superdex75 or superdex200 column, Amersham). Puri-
fied proteins will finally be treated with thrombin
(Sigma).
For any purified proteins, before treatment with
thrombin, a small amount of them were used for optimiz-
ing thrombin cutting concentrations: at room tempera-
ture, proteins were digested at a series of thrombin
concentrations (0.1, 0.5, 1, and 5 unit per milligram of
target protein) for 16 hours, and the concentration with
the best result was chosen as the actual one. If digestion
results were not good enough, try to increase or degrease
the amount of thrombin and test again. Once the
thrombin concentration was decided, the purified protein
was mixed with proper amounts of thrombin and dia-
lyzed in low salt buffer (20 mM Tris, 100 mM NaCl,
pH7.5) at 4°C for 16 hours. Resulted proteins were
checked by Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and used in crystallization
trials.
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